Psychelinx is designed for mental health professionals, particularly CBT psychologists and psychiatrists, who want clear, structured dashboards to review patient-generated data over time.
It is also intended for patients who are already in therapy and wish to track mood, symptoms, or subjective states between sessions under the guidance of a clinician.

No. Psychelinx does not provide diagnoses, treatment recommendations, crisis support, or medical alerts.
It is a digital self-monitoring tool designed to support reflection and facilitate discussion between a patient and a qualified mental health professional. All clinical decisions remain the sole responsibility of the clinician.

Psychelinx is a supportive tool used collaboratively by clinician and patient.
Brief daily check-ins are transformed into visual summaries that can be reviewed before or during sessions, helping both parties better understand what happens between appointments and focus sessions more effectively.

At launch, Psychelinx is intended to support work with anxiety and depressive disorders.

It is the clinician’s responsibility to determine whether a specific patient is suitable for using the app. Psychelinx does not assess suitability and does not assume clinical responsibility.

Based on the survey configured by the clinician, patients may record subjective information such as mood, symptoms, behaviours, and other experiential states.

All data entered is self-reported and reflects the patient’s subjective experience, including responses provided on numerical rating scales.

Yes. The clinician selects the most appropriate questionnaire based on the patient’s disorder and stage of therapy. Survey selection and use remain fully under the clinician’s professional discretion.

At launch, Psychelinx supports the monitoring of anxiety and depressive symptoms using brief, validated Ecological Momentary Assessment (EMA)–compatible questionnaires. Further applications are planned.

The questionnaires implemented in the app are derived from peer-reviewed research, stastically validated, and are designed for frequent, low-burden self-reporting in daily life contexts.

Depression
Psychelinx uses a 4-item EMA depression scale based on the work of Tamm et al., as described in: Tamm, S., et al. (2021). “Ecological Momentary Assessment versus Weekly Questionnaire Assessment of Change in Depression". This scale was developed to capture short-term fluctuations in depressive symptoms with minimal patient burden.

Anxiety
Psychelinx uses a 4-item EMA anxiety scale derived from Fortea et al., described in: Fortea, A., et al. (2019). “Development and Validation of a Smartphone-Based App for Longitudinal Assessment of Anxiety in Daily Life”. The scale was validated for repeated, real-world assessment of anxiety symptoms via smartphone-based EMA.

All questionnaires are used as self-report tools only and are intended to support clinical reflection and discussion, not diagnosis or automated clinical decision-making.

The clinician controls notification frequency on a per-patient basis. Reminders are delivered at randomised times across the day in line with Ecological Momentary Assessment (EMA) principles.

Discover the science behind Psychelinx.

Surveys consist of four questions and typically take no more than one to two minutes to complete.

No. Psychelinx does not provide real-time alerts and must not be used for emergency monitoring or crisis intervention.

In case of mental health emergencies, patients should contact local emergency services or crisis lines appropriate to their country.

Each patient has an individual dashboard showing visual summaries such as trend lines or pie charts. Data can be filtered over the last 7, 14, or 30 days, creating session-ready summaries that can be reviewed before or during appointments.

Yes. Dashboards have shared visibility: both clinician and patient see the same data, summarised in the same way. This design supports transparency and shared understanding within the therapeutic relationship.

Nothing happens. There are no penalties or consequences. Patients can complete their next check-in when prompted again or by opening the app manually.

Either party may unpair at any time. Once unpairing occurs, the clinician immediately loses access to the patient’s data within the app. Accounts can also be deleted directly from within the app.

Stopping use of Psychelinx does not affect the therapeutic relationship or continuity of care outside the app.

Psychelinx is currently available on iOS devices.

An Android version is planned for release in Spring 2026. You may sign up to the newsletter to be notified when it becomes available.

Yes. Patients may use Psychelinx independently for self-monitoring even when not paired with a clinician. In this case, data remains visible only to the patient unless a pairing is later established.